Corpus callosum volumetrics and clinical progression in early multiple sclerosis

M.A. SOTGIU¹, G. PIGA², V. MAZZARELLO¹, I.R. ZARBO³, A. CARTA⁴, L. SADERI⁵, S. SOTGIU⁴, M. CONTI⁶, L. SABA⁷, P. CRIVELLI²

¹Department of Biomedical Sciences, University of Sassari, Sassari, Italy
²Azienda Ospedaliero Universitaria di Sassari, Institute of Diagnostic Imaging 2, Sassari, Italy
³Department of Clinical, Surgery and Experimental Sciences, Section of Neurology, University of Sassari, Sassari, Italy
⁴Department of Clinical and Experimental Medicine, Unit of Child Neuropsychiatry, University of Sassari, Sassari, Italy
⁵Department of Medical, Surgical and Experimental Sciences, Clinical Epidemiology and Medical Statistics Unit, University of Sassari, Sassari, Italy
⁶Department of Clinical and Experimental Medicine, Institute of Diagnostic Imaging 2, University of Sassari, Sassari, Italy
⁷Department of Radiology, Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy

Abstract. – OBJECTIVE: Corpus callosum (CC) is commonly affected in multiple sclerosis (MS), with known association between CC atrophy and MS clinical activity. In this study, we assessed the association of callosal atrophy, lesions volume and residual CC volume with the clinical disability of early MS patients.

SUBJECTS AND METHODS: Thirteen MS subjects (9 female, mean age 36.9 years), studied with magnetic resonance imaging (MRI) were selected. MRI scans were performed at baseline (T0), at 6 (T1), 12 (T2), and 24 months (T3) from baseline. CC was segmented into three sections (genu, body, and splenium); callosal boundaries were outlined and all CC lesions were manually traced. Normal CC and CC lesion volumes were measured using a semiautomatic software.

RESULTS: From January 2014 to December 2016, all selected patients had confluent lesions on MRI at T3 with a significant increase in the size of confluent lesions compared to baseline (p=0.0007). At T1, a significant increase in the size of confluent (p=0.02) and single lesions located in the callosal body (p=0.04) was detected in patients with EDSS ≥1.5. Also, CC residual volume (CCR) rather than the whole CC volume (CCV) significantly correlated (p=0.03) with the clinical progression of MS in the whole cohort.

CONCLUSIONS: In early MS patients with higher EDSS at baseline, a significant increase in confluent CC lesions size is evident, particularly in the callosal body. Also, median CCR is significantly associated with MS progression in the whole MS group, regardless of initial EDSS. Given their significant association with disability, we encourage measuring CC body lesions and residual CC size for therapeutic decisions and prognostic planning in early MS.

Key Words: Corpus callosum, Volume, Multiple sclerosis, Demyelinating lesions, MRI.

Introduction

Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system, characterized by inflammation, demyelination and axonal loss. It is a frequent cause of neurological disability in young adults.

The corpus callosum (CC) is of peculiar interest in MS: with up to 250 million transversely oriented nerve fibers, CC is the largest commissural white matter tract connecting cortical and subcortical regions with the two brain hemispheres. CC lesions occur in up to 95% of MS patients and may strongly contribute to the development of both physical and cognitive impairments. Moreover, being composed of long inter-hemispheric fibers, CC may be representative of the changes in white matter occurring in the MS brain.

MS diagnosis is mainly based on magnetic resonance imaging (MRI), which is central also for prognostic purposes. Large cohort studies have shown association between CC lesions and CC atrophy and between CC atrophy and increased disease activity, which could help identify patients at high risk of future. Strategies have been developed to measure CC atrophy, from bidimensional approaches to more advanced volumetric techniques.
The purpose of the current study was to assess the relationship between CC atrophy, normal residual callosal volume (CCR) and CC lesions volume with the disability accumulation in selected MS patients at their early stage of disease.

Subjects and Methods

Subjects

In this retrospective study, 13 subjects who underwent MRI for diagnostic purposes from January 2014 to December 2016 were included. Inclusion criteria: age 18 years, MS diagnosis according to revised McDonald criteria\(^6\), and MRI scans performed at baseline (T\(_0\)), at 6 (T\(_1\)), 12 (T\(_2\)) and 24 months from baseline (T\(_3\)). Patients were excluded if additional diagnoses were present and if MRI analyses did not comply with the strict chronology. Age, gender, symptoms at onset, age at MS diagnosis, disease course\(^6\), Expanded Disability Status Scale (EDSS) and disease modifying treatments were also obtained from clinical files.

MRI Analysis and Segmentation

All MRIs were performed with a standardized protocol using a 1.5 T scanner Philips Achieva\(^6\) (Best, Netherlands). Sagittal FLAIR sequences (repetition time [TR] = 4800 ms; echo time [TE] = 297 ms; -0.6 continuous, 1.5-mm-thick, axial slices; matrix size = 200 × 200; field of view [FOV] = 240 × 240 mm\(^2\)) were examined at the different time points. Each acquisition was performed with special care to identify the correct alignment to have an optimal spatial co-registration.

The DICOM datasets were analyzed with the software 3D Slicer 4.10.1 (the open-source software platform is available at https://www.slicer.org). Two experienced neuroradiologists (PG and CP with 5 and 11 years in neuroimaging, respectively), blinded on clinical information, performed MRI analysis and segmentation according with standardized methods\(^19\)-\(^22\) (Figure 1).

Figure 1. Representative CC contouring and segmentation on four different MS subjects. A 30 y/o male subject (panel a) FLAIR-sequence, sagittal view; corpus callosum contoured with different color: dark green (lesion localized anteriorly, at genu level), light green (lesion localized in the middle of the body), light brown (lesion located more posteriorly in the body) and light blue (confluent lesion); yellow represents the corpus callosum residual. For each slice the lesions were outlined first, and then, the corpus callosum residual. A 21 y/o female subject (panel b) FLAIR-sequence, sagittal view: in light blue extended confluent lesion\(^6\); in the splenium, two further lesions are detectable (dark brown and white), in yellow the corpus callosum residual. A 36 y/o male subject, same of panel (panel c). FLAIR-sequence, axial view: a demyelinating lesion at the level of splenium is clearly visible in white. In yellow the corpus callosum residual. Axial images, as well as the coronal ones, were used to check the contour performed in sagittal. A 19 y/o female subject same of panel b (panel d). FLAIR-sequence, coronal view: two distinct lesions are visible, one more caudal and medial in light brown and one more cranial, at the left lateral limit of the corpus callosum, in light green; in yellow the corpus callosum residual.
Corpus callosum volumetrics and clinical progression in early multiple sclerosis

Following Cai et al\textsuperscript{22}, CC was segmented into three sections, corresponding to genu, body and splenium: the rostrum was merged with the genu and the isthmus with the body. Callosal boundaries were outlined using the “Editor” module of 3D Slicer. All CC lesions were manually traced and painted. A numeric code was assigned to each of them to identify the different type of lesion (single or confluent) and their location within the three parts of CC. The measurements of the following parameters were obtained: CCV (total volume of CC), SL (single lesion), CL (confluent lesion) and CCR (corpus callosum residual, i.e., CCV minus single and confluent lesions).

Manual segmentation of the outer boundaries was performed slice by slice on sagittal planes, with a further check on axial and coronal view to correct potential contouring mistakes. Most cranial and most caudal slices were excluded to avoid volume artefacts. Finally, a table containing data on CC volumes was generated and measures expressed as cubic centimeters (cc).

### Statistical Analysis

An ad hoc electronic form was used to collect all the variables in the study. Qualitative variables were described with absolute and relative (percentage) frequencies; quantitative variables were summarized with means (standard deviations, SD) or medians (interquartile ranges, IQR) in the case of parametric and non-parametric distribution, respectively. Qualitative variables were compared with Chi-squared or Fisher’s exact test when appropriate. Mann-Whitney or Student’s t-test were used to detect statistical differences in the comparison of non-parametric or parametric variables, respectively. The one-way analysis of variance (ANOVA) and Friedman’s test were performed to detect differences of quantitative variables at different time points depending on parametric and non-parametric distribution, respectively. A two-tailed p-value < 0.05 was considered statistically significant. The statistical software STATA version 16 (StataCorp, TX, USA) was used to perform all statistical computations.

### Results

Demographic and clinical characteristics of the patients (69.2% females) are summarized in Table I. Mean age at disease onset was 36.9 years. Twelve out of thirteen patients (92.3\%) had a relapsing-remitting (RR) course. Median EDSS score significantly worsened in all patients from baseline (1.5) to month 24 (3.0; \(p=0.005\); Table II).

### Table I. Demographic and descriptive analysis.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Female, n (%)</th>
<th>Mean (SD) age, years (n = 13)</th>
<th>Mean (SD) age at MS onset, years (n = 13)</th>
<th>Course, n (%)</th>
<th>DMT, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>9/13 (69.2)</td>
<td></td>
<td></td>
<td>RR 12/13 (92.3)</td>
<td>None 4/13 (30.8)</td>
</tr>
<tr>
<td>Mean (SD) age, years (n = 13)</td>
<td></td>
<td>41.5 (14.4)</td>
<td></td>
<td></td>
<td>IFN\textsubscript{b}-1a 3/13 (23.1)</td>
</tr>
<tr>
<td>Mean (SD) age at MS onset, years (n = 13)</td>
<td></td>
<td>36.9 (14.4)</td>
<td></td>
<td></td>
<td>Glatiramer acetate 2/13 (15.4)</td>
</tr>
<tr>
<td>Course, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>RR 12/13 (92.3)</td>
<td>Dimethyl fumarate 1/13 (7.7)</td>
</tr>
<tr>
<td>RR 12/13 (92.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IFN\textsubscript{b}-1b 1/13 (7.7)</td>
</tr>
<tr>
<td>RP 1/13 (7.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DMT: Disease modifying treatments; RR: relapsing-remitting; RP: relapsing-progressive; IFN: interferon.

### Table II. Comparison of variables from baseline to T\textsubscript{1}.

<table>
<thead>
<tr>
<th>Variables</th>
<th>(T_0)</th>
<th>(T_1)</th>
<th>(T_2)</th>
<th>(T_3)</th>
<th>(p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDSS\textsuperscript{a}</td>
<td>1.5 (1.0-2.5)</td>
<td>1.5 (1.5-4)</td>
<td>3 (1.5-3.5)</td>
<td>3 (1.5-4)</td>
<td>0.005*</td>
</tr>
<tr>
<td>CCR (cc)\textsuperscript{a}</td>
<td>10.5 (9.2-12.6)</td>
<td>10.08 (9.3-10.9)</td>
<td>9.4 (8.3-10)</td>
<td>9.52 (7.8-10.1)</td>
<td>0.03**</td>
</tr>
<tr>
<td>SPLENIUM SL (cc)\textsuperscript{a}</td>
<td>0.12 (0.08-0.2)</td>
<td>0.1 (0.07-0.12)</td>
<td>-</td>
<td>0.03 (0.02-0.04)</td>
<td>n.a.</td>
</tr>
<tr>
<td>BODY SL (cc)\textsuperscript{a}</td>
<td>0.09 (0.02-0.5)</td>
<td>0.12 (0.04-0.2)</td>
<td>0.09 (0.02-0.2)</td>
<td>0.1 (0.04-0.1)</td>
<td>0.75</td>
</tr>
<tr>
<td>GENU SL (cc)\textsuperscript{a}</td>
<td>0.14 (0.12-0.4)</td>
<td>0.1 (0.1-0.2)</td>
<td>-</td>
<td>-</td>
<td>0.18</td>
</tr>
<tr>
<td>CL (cc)\textsuperscript{b}</td>
<td>0.8 (0.27-1.02)</td>
<td>1.02 (0.7-1.28)</td>
<td>1.07 (0.7-1.2)</td>
<td>1.15 (0.8-1.2)</td>
<td>0.007***</td>
</tr>
<tr>
<td>Mean (SD) CCV (cc)</td>
<td>12.1 (±2.6)</td>
<td>11.8 (±2.3)</td>
<td>10.5 (±1.4)</td>
<td>10.5 (±1.8)</td>
<td>0.10</td>
</tr>
</tbody>
</table>

EDSS: Expanded Disability Status Scale; CCR: corpus callosum residual; SL: single lesions; CL: confluent lesions; CCV: corpus callosum volume; cc: cubic centimeters; n.a.: not applicable; §: Median value (interquartile range)

*\(T_0\) vs. \(T_1\) = 0.01; \(T_0\) vs. \(T_2\) = 0.02.

**\(T_0\) vs. \(T_1\) = 0.009; \(T_0\) vs. \(T_2\) = 0.03; \(T_1\) vs. \(T_2\) = 0.006.

***\(T_0\) vs. \(T_1\) = 0.03; \(T_0\) vs. \(T_2\) = 0.006; \(T_0\) vs. \(T_3\) = 0.0006.
At T₀, 46.1% of subjects had T2/FLAIR-weighted hyperintense lesions in the splenium, 23.1% in the body and 23.1% in the genu of the CC.

At T₁, all patients had CL on CC which were significantly larger compared to the previous time points (p=0.007). On the contrary, no significant mean CCV decrease was detected over time (Table II).

Regarding CCR, the median volume was 10.5 cc at baseline and 9.5 cc at T₁ (p=0.03). CCR volume was also significantly reduced at T₂ (p=0.009) and when comparing T₁ with T₁ (p=0.006) (Table II and Figure 2). Immunomodulatory treatments (listed on Table I) did not significantly influence disability accumulation, nor the whole CC volume or the volume of CC lesions (not shown).

Finally, stratifying according to the median EDSS at onset, already at T₁ there was a statistically significant size increase of the callosal body lesions (p=0.04) and of the CL (p=0.02) in those patients with baseline EDSS ≥1.5 (Table III). This tendency was maintained throughout the whole observational period.

**Discussion**

In the last 20 years, CC has attracted great interest in neuroimaging for its prognostic role in neurodegenerative disorders²³,²⁴. Having demarcated two-dimensional limits on mid-sagittal T1-weighted imaging, CC can be easily identified on conventional MRI²⁵ for manual measures of its atrophy²⁶. We adopted a semiautomatic software to evaluate the relationship between callosal volume reduction on MRI and clinical changes in a cohort of MS patients. We took special care to ensure the reproducibility of CC volume and sub-components on MRI, as suggested¹⁹.

A timely detection of callosal atrophy in patients at their first demyelinating attack can predict the development of definite MS²⁶,²⁷. Our results suggested that CC residual volume (CCR), rather than CC global atrophy, is progressively reduced (T₁-T₂) during the initial MS stages³,²²-²⁵. On the contrary, no association was found between the atrophy of the whole CC and disability accumulation, neither in the entire MS group nor when stratifying patients according to EDSS severity at onset. In our study, CCR (i.e., the CCV minus the single and confluent lesions) does not reflect the increase in CC lesions volume. This can be attributed to the removal of confounding factors, such as the inflammatory lesional edema and the spurious augmentation of CC volume. Studies over the last 10 years confirmed the uncertain relationship between CC atrophy and disability: a moderate correlation is reported in some studies, but not in others²⁸,²⁹. Also, the volume of CC lesions, particularly those in the CC body, increased at T₁ and significantly progressed over the following years in patients with higher EDSS at onset. Therefore, in addition to CCR, we may also propose a prognostic role to the callosal body lesions²³-²⁹.
Finally, we acknowledge some limitations in this study. First, it has a retrospective cross-sectional nature, and it includes a limited cohort of patients (due to the strict temporal and alignment criteria). A larger, prospective study would be important to confirm these preliminary results. Second, MRI analysis was limited to CC, with no other brain and spinal regions investigated. We also quantified CC volume semi-automatically drawing CC contour on non-isotropic images, while a fully automated approach on isotropic images would be the gold standard for volumetric determinations. However, we consider this a minor limitation due to the high value of reproducibility reported in the literature and the strict adherence to the alignment plane that has been followed.
Conclusions

The reduction of CCR and the increase of confluent lesions in the CC body are associated with higher disability risk in MS. Our findings strengthen the idea that focal variations of callosal lesions in early MS stages may be central for developing proper treatment planning. Larger studies are needed to confirm CC as a reliable prognostic biomarker in MS.

Acknowledgments

Thanks to Elisa Sotgiu and Thomas Leonard-Roy, Departments of Comparative Literature and English, Harvard University, Cambridge, MA (USA) for help with proofreading.

Ethical Approval and Informed Consent

All procedures performed in the studies involving human participants were in accordance with the Ethical Standards of the Institutional and/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, informed consent is not required.

Consent for Publication

Not applicable.

Conflict of Interests

The authors declare that they have no competing interests.

Funding

This study was funded by “Fondo di Ateneo per la ricerca 2019”, University of Sassari.

Authors’ Contributions

MAS: study concept and design, literature research, manuscript preparation; GP: literature research, data analysis; VM: study design, literature research; IRZ: clinical data collection; AC: data collection, manuscript review and editing; LS: statistical analysis; SS: manuscript review and editing; MC: manuscript review; LS: manuscript review and editing. All authors read and approved the final manuscript.

References

Corpus callosum volumetrics and clinical progression in early multiple sclerosis


